

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天安卓健有限公司

TIAN AN MEDICARE LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 383)

SUPPLEMENTAL ANNOUNCEMENT IN RESPECT OF ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025 AND INTERIM REPORT FOR THE SIX MONTHS ENDED 30 JUNE 2026

References are made to (i) the annual report of Tian An Medicare Limited (the “**Company**”) for the year ended 31 December 2025 published by the Company on 16 April 2026 (the “**2025 Annual Report**”) and (ii) the interim report of the Company for the six months ended 30 June 2026 published by the Company on 14 September 2026 (the “**2026 Interim Report**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the 2025 Annual Report and the 2026 Interim Report.

The 2025 Annual Report

The board of directors of the Company (the “**Board**”) would like to provide supplemental information on the 2025 Annual Report in relation to the details of use of net proceeds from the Rights Issue as below.

Intended use	Planned use of the net proceeds HK\$'000	Net proceeds used as at 31 December 2025 HK\$'000	Remaining balance of the net proceeds unutilized as at 31 December 2025 HK\$'000	Expected timeline of utilization
Investment opportunities	200,000	25,564	174,436	end of 2027
General working capital	47,792	47,792	–	N/A
Share repurchase	61,500	1,982	59,518	end of 2026
	<u>309,292</u>	<u>75,338</u>	<u>233,954</u>	

The 2026 Interim Report

The Board would also like to provide supplemental information on the 2026 Interim Report in relation to the details of use of net proceeds from the Rights Issue as below.

Intended use	Planned use of the net proceeds HK\$'000	Net proceeds used as at 30 June 2026 HK\$'000	Remaining balance of the net proceeds unutilized as at 30 June 2026 HK\$'000	Expected timeline of utilization
Investment opportunities	200,000	25,564	174,436	end of 2027
General working capital	47,792	47,792	–	N/A
Share repurchase	61,500	61,500	–	N/A
	<u>309,292</u>	<u>134,856</u>	<u>174,436</u>	

Save as disclosed above, all other information and content set out in the 2025 Annual Report and the 2026 Interim Report remain unchanged. This announcement is supplemental to and should be read in conjunction with the 2025 Annual Report and the 2026 Interim Report.

On behalf of the Board
Tian An Medicare Limited
Kong Muk Yin
Executive Director

Hong Kong, 29 September 2026

As at the date of this announcement, the Board comprises Mr. Kong Muk Yin and Mr. Guo Meibao being Executive Directors; Mr. Lee Seng Hui (Chairman), Mr. Mark Wong Tai Chun, Mr. Zhou Haiying, Mr. Gao Zhaoyuan and Ms. Zhang Yuanyuan being Non-Executive Directors; and Dr. Xia Xiaoning, Dr. Wong Wing Kuen, Albert, Ms. Yang Lai Sum, Lisa and Mr. Cao Dan being Independent Non-Executive Directors.